Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: Validation by whole body FDG-PET and conventional diagnostics

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2685-2690

  Mruck, Stefan ^a   Baum, Richard Paul ^a,b   Rinne, Daniela ^a   Hör, Gustav ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Central Clinic Bad Berka   (Germany)

Author keywords

F 18 FDG PET; LIA; Luminescenceimmunoassay; Malignant melanoma; PET; Positron emission tomography; Protein S100; Radioimmunoassay; RIA; Staging; Thymidine kinase; Tumor marker

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN S 100; THYMIDINE KINASE; TUMOR ANTIGEN;

ADULT; AGED; BLOOD LEVEL; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; LUMINESCENCE; LYMPH NODE; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032809471     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Garbe C, Dummer R, Kaufmann, R, Tilgen W (Hrsg.): Dermatologische Onkologie. Springer Verlag, 1997.
2. Carrel S, Rimoldi D: Melanoma-associated Antigens. Eur J Cancer 29A: 1903-1907, 1993.
3. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of Melanin-Related Metabolites as Markers of Melanoma Progression. Cancer 73: 629-636, 1994.
4. Clark WH, Jr Lynn F, Bernardino EA, Mihm MC: The Histogenesis and Biologic Behavior of Primary Human Malignant Melanomas of the Skin. Cancer Res 29: 705-727, 1969.
5. Breslow A: Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma. Ann Surg 172: 902-908, 1970.
6. Warburg O: Über den Stoffwechsel der Carcinomzelle. Klin Wochenschr 4: 534-536, 1925.
7. Hör G, Werner R, Klusmann A, Baum RP, Krause BJ, Maul FD, Holzmann H: Diagnostische Beiträge der Nuklearmedizin für den Dermatologen - Eine Standort-Analyse nach 15jähriger Kooperation. Z Hautkr 71: 594-610, 1996.
8. Hör G, Adams S, Baum RP, Hertel A, Adamietz IA, Böttcher HD, Kollath J: Impact of Single Photon Emission Computed Tomography and Positron Emission Tomography on Diagnostic Oncology. Diagn Oncol 4: 297-321, 1997.
9. Argenyi EE, Urdaneta LF, Whitaker DC, Uygur GS, Ponto LLB, Hichawa RD, Watkins GL, Kirchner PT: Clinical utility of F-18 FDG and PET imaging in detecting metastatic melanoma (abstr No 871). J Nucl Med 36: 193P, 1995.
10. Donate R: Perspectives in S-100 protein biology. Cell Calcium 72: 713-726, 1991.
11. Von Schoultz E, Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U: Prognostic value of serum analyses of S-100b protein in malignant melanoma. Melanoma Research 6: 133-137, 1996.
12. Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A: S100 Protein: A marker for human malignant melanomas? Lancet 1: 869-871, 1981.
13. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Comm 19: 739-747, 1965.
14. Moore BW, Mac Gregor D: Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem 240: 1647-1653, 1965.
15. Moore BW: Chemistry and biology of two proteins S100 and 14-3-2 specific to the nervous system. Int Rev Neurobiol 15; 215, 1972.
16. Isobe T, Tsugita A, Okuyama T: The amino acid sequence and the subunit structure of bovine brain S100 protein (PAP-1b). J Neurochem 30: 921-923, 1978.
17. Isobe T, Okuyama T: The amino acid sequence of S100 protein (PAP-1b protein) and ist relationship to calcium binding proteins. Eur J Biochem 89: 379-388, 1978.
18. Persson L, Hårdemark H-G, Gustafsson J, Rundström G, Mendel-Hartvig I, Esscher T, Påhlman S: S-100 Protein and Neuron-Specific Enolase in Cerebrospinal Fluid and Serum: Markers of Cell Damage in Human Central Nervous System. Stroke 18: 911-918, 1987.
19. Nygaard Ø, Langbakk B, Romner B: Age- and Sex-Related Changes of S-100 Protein Concentrations in Cerebrospinal Fluid and Serum in Patients with No Previous History of Neurological Disorder. Clin Chem 43: 541-543, 1997.
20. Ingebrigtsen T, Romner B, Kongstad P, Langbakk B: Increased serum levels of protein S-100 after head injury: a biochemical serum marker with prognostic value? Journal of Neurology, Neurosurgery and Psychiatry 59: 103-104, 1995.
21. Gatter KC, Ralfkiaer E, Skinner J et al: An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 38: 1353-1357, 1985.
22. Smoller BR: Immunohistochemistry in the diagnosis of malignant melanoma. Clinics Dermatol 9: 235-241, 1991.
23. Paul E, Wen D-R, Cochran AJ: Variations in S-100 protein expression in naevocellular naevi may be related to metabolic activity. Br J Dermatol 116: 371-378, 1987.
24. Bei Guo H, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D: Clinical Significance of Serum S100 in Metastatic Malignant Melanoma. Eur J Cancer 31A: 924-928, 1995.
25. Hallek M, Wanders L, Strohmeyer S, Emmerich B: Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65: 1-5, 1992.